var data={"title":"Dextroamphetamine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dextroamphetamine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6007?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dextroamphetamine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dextroamphetamine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=dextroamphetamine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dextroamphetamine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708681\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Abuse potential:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines have a high potential for abuse. Administration of amphetamines for prolonged periods of time may lead to drug dependence and must be avoided. Pay particular attention to the possibility of subjects obtaining amphetamines for nontherapeutic use or distribution to others; prescribe and dispense the drugs sparingly.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cardiovascular events: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Misuse of amphetamines may cause sudden death and serious cardiovascular adverse reactions.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158794\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Dexedrine;</li>\n      <li>ProCentra;</li>\n      <li>Zenzedi</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158795\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Dexedrine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158811\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Central Nervous System Stimulant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158798\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Narcolepsy:</b> Oral: Initial: 10 mg once daily; may increase in increments of 10 mg at weekly intervals until optimal response is obtained; usual dosage: 5 to 60 mg  daily in divided doses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158805\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=dextroamphetamine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dextroamphetamine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Attention-deficit/hyperactivity disorder (ADHD):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Children 3 to 5 years:</i> Oral: Immediate release tablets and oral solution: Initial: 2.5 once daily; may increase in increments of 2.5 mg at weekly intervals until optimal response is obtained; maximum dose: 40 mg daily (Dopheide 2009). <b>Note:</b> Although FDA approved, current guidelines do not recommend use in children &le;5 years due to insufficient evidence (AAP 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Children &ge;6 years and Adolescents:</i> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Immediate release tablets and  oral solution: Initial: 5 mg once or twice daily; may increase in increments of 5 mg at weekly intervals until optimal response is reached; maximum dose: 40 mg daily (Dopheide 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Extended release capsules: Initial: 5 mg once or twice daily; may increase in increments of 5 mg at weekly intervals until optimal response is reached. Maximum dose: 40 mg daily (Dopheide 2009); a maximum daily dose of 60 mg in divided doses has been used in children &gt;50 kg (Dopheide 2009; Pliszka 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Narcolepsy:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Children 6 to 12 years:</i> Oral: Initial: 5 mg once daily; may increase in increments of 5 mg at weekly intervals until optimal response is obtained; usual dosage: 5 to 60 mg  daily in divided doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Children &gt;12 years and Adolescents:</i> Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158799\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing; start at lowest dose. Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15796031\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15796032\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158775\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dexedrine: 5 mg, 10 mg, 15 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c blue #1 aluminum lake, fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg, 15 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ProCentra: 5 mg/5 mL (473 mL [DSC]) [contains benzoic acid, saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ProCentra: 5 mg/5 mL (473 mL) [contains benzoic acid, saccharin sodium; bubble-gum flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/5 mL (473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dexedrine: 5 mg [DSC], 10 mg [DSC] [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zenzedi: 2.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zenzedi: 5 mg [scored; contains fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zenzedi: 7.5 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zenzedi: 10 mg [scored; contains fd&amp;c blue #2 (indigotine), fd&amp;c red #40, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zenzedi: 15 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c blue #2 (indigotine), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zenzedi: 20 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zenzedi: 30 mg [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158759\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158813\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874427\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Dexedrine Spansule:  <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017078s049lbl.pdf#page=9&amp;token=aLpv7oY2FWYyI2nvM7X5cfTOz4WYd3DyYSia2w9WJAeJzeKKl0ccZO7xGI+Ue1eseEZGl+BTq/YlXlysDJWkHhlu1qZ37i9ZVnTcM3keNnrfwv8l4MpaSRj80nnHMfJ7&amp;TOPIC_ID=13219\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017078s049lbl.pdf#page=9</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">ProCentra:  http://fscpediatrics.com/pdf/Pages%20ProCentra%20med%20guide.pdf </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Zenzedi: <a target=\"_blank\" href=\"http://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=d6394df5-f2c9-47eb-b57e-f3e9cfd94f84&amp;token=kd+AjwwVx9Pd5RuPgNpo3CCEbew3BJSVnJ0I9mGwsEMidhJSn/Yy3LavbyJZAEy6OShKW4VE6D5f+MoVym2wsCTcG93z/5LQ10K5ukwZUvgwWoZ+blWRTE5YkPcmYpRm&amp;TOPIC_ID=13219\" target=\"_blank\">http://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=d6394df5-f2c9-47eb-b57e-f3e9cfd94f84</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158777\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer initial dose upon awakening; do not administer doses late in the evening due to potential for insomnia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release tablets and oral solution: If needed, 1 to 2 additional doses may be administered at intervals of 4 to 6 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release and sustained release capsules: Do not crush sustained release drug products. Formulations may be used for once-daily administration, if appropriate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158776\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Attention-deficit/hyperactivity disorder:</b> Treatment of attention-deficit/hyperactivity disorder (ADHD) as part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children 3 to 16 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Narcolepsy:</b> Treatment of narcolepsy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158819\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dexedrine may be confused with dextran, Excedrin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dextroamphetamine may be confused with dexamethasone</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158766\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiomyopathy, hypertension, palpitations, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Aggressive behavior, dizziness, dysphoria, euphoria, exacerbation of tics, Gilles de la Tourette syndrome, headache, insomnia, mania, overstimulation, psychosis, restlessness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Change in libido, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, constipation, diarrhea, unpleasant taste, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Frequent erections, impotence, prolonged erection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Dyskinesia, rhabdomyolysis, tremor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Accommodation disturbances, blurred vision</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158780\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, angioedema, anaphylaxis) or idiosyncrasy to amphetamine, dextroamphetamine, other sympathomimetic amines, or any component of the formulation; advanced arteriosclerosis, symptomatic cardiovascular disease, moderate-to-severe hypertension; hyperthyroidism; glaucoma; agitated states; patients with a history of drug abuse; during or within 14 days of stopping monoamine oxidase inhibitor (MAOI) therapy (including MAOIs such as linezolid or intravenous methylene blue).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for amphetamines is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158763\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: <b>[US Boxed Warning]: Use has been associated with serious cardiovascular events including sudden death in patients with preexisting structural cardiac abnormalities or other serious heart problems (sudden death in children and adolescents; sudden death, stroke and MI in adults).</b> These products should be avoided in the patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that could increase the risk of sudden death. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy. Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during treatment should undergo a prompt cardiac evaluation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Amphetamines may impair the ability to engage in potentially hazardous activities (driving, operating machinery).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral vasculopathy: Stimulants are associated with peripheral vasculopathy, including Raynaud phenomenon; signs/symptoms are usually mild and intermittent, and generally improve with dose reduction or discontinuation. Digital ulceration and/or soft tissue breakdown have been observed rarely; monitor for digital changes during therapy and seek further evaluation (eg, rheumatology) if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Visual disturbance: Difficulty in accommodation and blurred vision has been reported with the use of stimulants.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse potential: <b>[US Boxed Warning]: Potential for drug dependency exists; prolonged use may lead to drug dependency.</b> Use is contraindicated in patients with history of ethanol or drug abuse. Prescriptions should be written for the smallest quantity consistent with good patient care to minimize possibility of overdose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: Use with caution in patients with hypertension and other cardiovascular conditions that might be exacerbated by increases in blood pressure or heart rate. Use is contraindicated in patients with moderate-to-severe hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disorders: Use with caution in patients with preexisting psychosis or bipolar disorder. May exacerbate symptoms of behavior and thought disorder or induce mixed/manic episode, respectively. New onset psychosis or mania may also occur with stimulant use. Observe for symptoms of aggression and/or hostility.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Limited information exists regarding amphetamine use in seizure disorder (Cortese, 2013).  The manufacturer recommends use with caution in patients with a history of seizure disorder; may lower seizure threshold leading to new onset or breakthrough seizure activity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tourette syndrome/tics: Use with caution in patients with Tourette syndrome or other tic disorders. Stimulants may exacerbate tics (motor and phonic) and Tourette syndrome; however, evidence demonstrating increased tics is limited. Evaluate for tics and Tourette syndrome prior to therapy initiation (AACAP [Murphy 2013, Pliszka 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome may occur when dextroamphetamine is used in combination with other serotonergic agents (eg, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, St. John's wort, tryptophan), agents that impair metabolism of serotonin (eg, monoamine oxidase inhibitors), or CYP2D6 inhibitors that impair metabolism of dextroamphetamine. Concomitant use with monoamine oxidase inhibitors is contraindicated. If concomitant use of dextroamphetamine with serotonergic drugs or CYP2D6 inhibitors is indicated, initiate dextroamphetamine at a low dose and monitor patient closely for signs and symptoms of serotonin syndrome. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use caution in this age group due to CNS stimulant adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Appetite suppression may occur,  particularly in children. Use of stimulants has been associated with weight loss and slowing  of growth rate; monitor growth rate and weight during treatment. Treatment interruption may be necessary in patients who are not increasing in height or gaining weight as expected.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse  (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates.  See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Abrupt discontinuation following high doses or for prolonged periods may result in symptoms for withdrawal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299162\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158768\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9341&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acebrophylline: May enhance the stimulatory effect of CNS Stimulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alkalinizing Agents: May decrease the excretion of Amphetamines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ammonium Chloride: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the excretion of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihistamines: Amphetamines may diminish the sedative effect of Antihistamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihypertensive Agents: Amphetamines may diminish the antihypertensive effect of Antihypertensive Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: May diminish the stimulatory effect of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ascorbic Acid: May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: May decrease the excretion of Amphetamines.<b> Exceptions: </b>Brinzolamide; Dorzolamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethosuximide: Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Acidifying Agents: May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: Amphetamines may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May diminish the stimulatory effect of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methenamine: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Amphetamines. While linezolid and tedizolid may interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to monographs specific to those agents for details.<b> Exceptions: </b>Linezolid; Tedizolid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May decrease the serum concentration of Amphetamines. More specifically, the ascorbic acid (vitamin C) in many multivitamins may decrease amphetamine concentrations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Amphetamines. Specifically, vitamin C may impair absorption of amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: Amphetamines may enhance the analgesic effect of Opioid Analgesics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: Amphetamines may decrease the serum concentration of PHENobarbital. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Amphetamines may decrease the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May increase the absorption of Dextroamphetamine. Specifically, the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urinary Acidifying Agents: May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24522698\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Amphetamine serum levels may be reduced if taken with acidic food, juices, or vitamin C. Management: Monitor response when taken concurrently.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158770\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6470944\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have been observed in animal reproduction studies. The majority of human data is based on illicit amphetamine/methamphetamine exposure and not from therapeutic maternal use (Golub 2005). Use of amphetamines during pregnancy may lead to an increased risk of premature birth and low birth weight; newborns may experience symptoms of withdrawal. Behavioral problems may also occur later in childhood (LaGasse 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15041842\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Dextroamphetamine is present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of dextroamphetamine ranged from 3.9% to 13.8% in a study when compared to a weight-adjusted maternal dose of 15 to 45 mg/day.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000). However some sources note breastfeeding should only be considered if the RID is &lt;5% for psychotropic agents (Larsen 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The RID of dextroamphetamine was calculated using average milk concentrations of 0.066 to 0.313 mcg/mL, providing an absolute infant dose via breast milk of 10 to 47 mcg/kg/day (median: 21 mcg/kg/day). This milk concentration was obtained following maternal administration of dextroamphetamine 15 to 45 mg/day (average: 18 mg/day) in divided doses to four women. Dextroamphetamine was detected in the plasma of two of the three infants tested. Adverse events were not reported in the breastfed infants (Ilett 2007).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The majority of human data is based on illicit amphetamine/methamphetamine exposure and not from therapeutic maternal use (Golub 2005). Increased irritability, agitation, and crying have been reported in breastfeeding infants. As a class, amphetamines may also decrease milk supply (ACOG 2011). Breastfeeding is not recommended (AAP 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158772\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Cardiac evaluation should be completed on any patient who develops exertional chest pain, unexplained syncope, and any symptom of cardiac disease during treatment with stimulants; behavioral changes; signs of peripheral vasculopathy (eg, digital changes); growth and weight in children;  CNS activity in all patients; signs of misuse, abuse, or addiction.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When used for the treatment of ADHD, thoroughly evaluate for cardiovascular risk.   Monitor heart rate, blood pressure, and consider obtaining ECG prior to initiation (Vetter, 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158762\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Amphetamines are noncatecholamine, sympathomimetic amines that promote release of catecholamines (primarily dopamine and norepinephrine) from their storage sites in the presynaptic nerve terminals.  A less significant mechanism may include their ability to block the reuptake of catecholamines by competitive inhibition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158779\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration of action: Immediate release: 4 to 6 hours; extended release: 8 hours (Dopheide 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP monooxygenase and glucuronidation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Adults: 10 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Immediate release: ~3 hours; Sustained release: ~8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine; urinary excretion is pH dependent and is increased with acid urine (low pH)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5989310\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Dexedrine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (90): $2,096.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (90): $2,096.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (90): $2,096.09</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Dextroamphetamine Sulfate ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (90): $364.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (90): $455.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (90): $580.59</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Dextroamphetamine Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/5 mL (473 mL): $863.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (ProCentra Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/5 mL (473 mL): $960.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Dextroamphetamine Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $290.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $315.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Zenzedi Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (100): $815.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $815.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (100): $815.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $815.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $815.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $815.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $815.74</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038597\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Dexamphetamine (AU);</li>\n      <li>Dexamphetamini Sulfas (CH);</li>\n      <li>Dexedrine (BB, GB, NO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Association of Pediatrics, Section on Breastfeeding. Breastfeeding and the use of human milk. <i>Pediatrics</i>. 2012;129(3):e827-e841<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/22371471/pubmed\" target=\"_blank\" id=\"22371471\">22371471</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee Opinion: No. 479, &ldquo;Methamphetamine Abuse in Women of Reproductive Age,&rdquo; <i>Obstet Gynecol</i>, 2011, 117(3):751-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/21343793/pubmed\" target=\"_blank\" id=\"21343793\">21343793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper WO, Habel LA, Sox CM, et al, &ldquo;ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults,&rdquo; <i>N Engl J Med</i>, 2011, 365(20):1896-904.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/22043968/pubmed\" target=\"_blank\" id=\"22043968\">22043968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cortese S, Holtmann M, Banaschewski T, et al; European ADHD Guidelines Group. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medication in children and adolescents. <i>J Child Psychol Psychiatry</i>. 2013;54(3): 227-246.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/23294014/pubmed\" target=\"_blank\" id=\"23294014\">23294014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dexedrine (dextroamphetamine) [prescribing information]. Horsham, PA: Amedra Pharmaceuticals LLC; May 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dexedrine (dextroamphetamine) sustained release capsules and tablets [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dexedrine Spansule (dextroamphetamine) sustained-release capsules [prescribing information]. Horsham, PA: Amedra Pharmaceuticals LLC; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dexedrine Spansule (dextroamphetamine) sustained-release capsules [prescribing information]. Horsham, PA: Amedra Pharmaceuticals LLC; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dextroamphetamine sulfate extended-release capsules [prescribing information]. South Plainfield, NJ: Able Laboratories Inc; February 2004.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dextroamphetamine sulfate tablets [prescribing information]. Pomona, NY: Barr Laboratories Inc; March 2000.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dextroamphetamine sulfate tablets [prescribing information]. St. Louis, MO: Mallinckrodt Inc; October 2001.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dextrostat (dextroamphetamine) tablets [prescribing information]. Newport, KY: Shire US Inc; May 2003.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. <i>Pharmacotherapy</i>. 2009;29(6):656-679.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/19476419/pubmed\" target=\"_blank\" id=\"19476419\">19476419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fratto G, Manzon L. Use of psychotropic drugs and associated dental diseases. <i>Int J Psychiatry Med.</i> 2014;48(3):185-197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/25492713/pubmed\" target=\"_blank\" id=\"25492713\">25492713</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Golub M, Costa L, Crofton K, et al, &quot;NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Amphetamine and Methamphetamine,&quot; <i>Birth Defects Res B Dev Reprod Toxicol</i>, 2005, 74(6):471-584.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/16167346/pubmed\" target=\"_blank\" id=\"16167346\">16167346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta S, Ghaly N, and Dewan M, &quot;Augmenting Fluoxetine With Dextroamphetamine to Treat Refractory Depression,&quot; <i>Hosp Community Psychiatry</i>, 1992, 43(3):281-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/1555827/pubmed\" target=\"_blank\" id=\"1555827\">1555827</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Habel LA, Cooper WO, Sox CM, et al, &ldquo;ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-Aged Adults,&rdquo; 2011, <i>JAMA</i>, 306(24):2673-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/22161946/pubmed\" target=\"_blank\" id=\"22161946\">22161946</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ilett KF, Hackett LP, Kristensen JH, Kohan R. Transfer of dexamphetamine into breast milk during treatment for attention deficit hyperactivity disorder. <i>Br J Clin Pharmacol</i>. 2007;63(3):371-375.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/17380592/pubmed\" target=\"_blank\" id=\"17380592\">17380592</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women [published correction appears in <i>N Engl J Med</i>. 2000;343(18):1348]. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LaGasse LL, Derauf C, Smith LM, et al, &quot;Prenatal Methamphetamine Exposure and Childhood Behavior Problems at 3 and 5 Years of Age,&quot; <i>Pediatrics</i>, 2012, 129(4):681-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/22430455/pubmed\" target=\"_blank\" id=\"22430455\">22430455</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/26344706/pubmed\" target=\"_blank\" id=\"26344706\">26344706</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mattson RH and Calverley JR, &ldquo;Dextroamphetamine-Sulfate-Induced Dyskinesias,&rdquo; <i>JAMA</i>, 1968, 204(5):400-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/5694457/pubmed\" target=\"_blank\" id=\"5694457\">5694457</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murphy TK, Lewin AB, Storch EA, et al. Practice parameter for the assessment and treatment of children and adolescents with tic disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2013;52(12):1341-1359.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/24290467/pubmed\" target=\"_blank\" id=\"24290467\">24290467</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health , &ldquo;Attention Deficit Hyperactivity Disorder, The NICE Guideline on Diagnosis and Management of ADHD in Children, Young People and Adults,&rdquo; National Clinical Practice Guideline Number 72, 2008:1-664. Available at https://www.nice.org.uk/guidance/CG72</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker G and Brotchie H, &quot;Do the Old Psychostimulant Drugs Have a Role in Managing Treatment-Resistant Depression?&quot; <i>Acta Psychiatr Scand</i>, 2010, 121(4):308-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/19594481/pubmed\" target=\"_blank\" id=\"19594481\">19594481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perrin JM, Friedman RA, Knilans TK; Black Box Working Group; Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. <i>Pediatrics</i>. 2008;122(2):451-453.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/18676566/pubmed\" target=\"_blank\" id=\"18676566\">18676566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(7):894-921.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/17581453/pubmed\" target=\"_blank\" id=\"17581453\">17581453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ProCentra (dextroamphetamine) [prescribing information]. Newport, KY: Independence Pharmaceuticals; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vetter VL, Elia J, Erickson CH, et al; American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee; American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. <i>Circulation</i>. 2008;117(18):2407-2423.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/18427125/pubmed\" target=\"_blank\" id=\"18427125\">18427125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wolraich M, Brown L, Brown, RT, et al; Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. <i>Pediatrics</i>. 2011;128(5):1007-1022.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dextroamphetamine-drug-information/abstract-text/22003063/pubmed\" target=\"_blank\" id=\"22003063\">22003063</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9341 Version 187.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708681\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F158794\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F158795\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F158811\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F158798\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F158805\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F158799\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15796031\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15796032\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F158775\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F158759\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F158813\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874427\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F158777\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F158776\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F158819\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F158766\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F158780\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F158763\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299162\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F158768\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F24522698\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F158770\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6470944\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F15041842\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F158772\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F158762\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F158779\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5989310\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038597\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9341|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dextroamphetamine-patient-drug-information\" class=\"drug drug_patient\">Dextroamphetamine: Patient drug information</a></li><li><a href=\"topic.htm?path=dextroamphetamine-pediatric-drug-information\" class=\"drug drug_pediatric\">Dextroamphetamine: Pediatric drug information</a></li></ul></div></div>","javascript":null}